SIC
BMRN icon

SJS Investment Consulting’s BioMarin Pharmaceuticals BMRN Stock Holding History

SJS Investment Consulting’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$50.2K Buy
877
+172
+24% +$9.42K 0.01% 463
2026
Q1 		$39.8K Buy
705
+126
+22% +$7.35K ﹤0.01% 468
2025
Q4 		$34.4K Buy
579
+566
+4,354% +$30.8K ﹤0.01% 477
2025
Q3 		$705 Buy
+13
New +$743 ﹤0.01% 1119
2025
Q2 		– Sell
-21
Closed -$1.49K – 1569
2025
Q1 		$1.49K Buy
21
+17
+425% +$1.14K ﹤0.01% 852
2024
Q4 		$263 Sell
4
-24
-86% -$1.61K ﹤0.01% 1422
2024
Q3 		$1.97K Buy
28
+10
+56% +$836 ﹤0.01% 793
2024
Q2 		$1.48K Sell
18
-1
-5% -$83 ﹤0.01% 865
2024
Q1 		$1.66K Buy
19
+3
+19% +$269 ﹤0.01% 833
2023
Q4 		$1.54K Sell
16
-6
-27% -$531 ﹤0.01% 776
2023
Q3 		$1.95K Buy
22
+2
+10% +$178 ﹤0.01% 643
2023
Q2 		$1.73K Buy
20
+6
+43% +$565 ﹤0.01% 662
2023
Q1 		$1.36K Sell
14
-9
-39% -$933 ﹤0.01% 747
2022
Q4 		$2.38K Buy
23
+10
+77% +$939 ﹤0.01% 556
2022
Q3 		$1K Buy
+13
New +$1.16K ﹤0.01% 632
2022
Q1 		$0 Buy
+3
New +$251 ﹤0.01% 755

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

SJS Investment Consulting's BMRN Position: Q2 2026 in Review

SJS Investment Consulting increased its BioMarin Pharmaceuticals (BMRN) stake by 24% in Q2 2026, buying an estimated $9.42K and bringing the position to 877 shares worth $50.2K. The position accounts for 0.01% of the portfolio, ranked #463.

SJS Investment Consulting first reported a position in BMRN in Q1 2022 and has held it in 16 quarters since. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • SJS Investment Consulting held 877 shares of BioMarin Pharmaceuticals worth $50.2K as of Q2 2026.
  • SJS Investment Consulting bought 172 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $9.42K.
  • BioMarin Pharmaceuticals made up 0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #463 holding.
  • SJS Investment Consulting first reported a position in BioMarin Pharmaceuticals in Q1 2022 and has held it in 16 quarters since.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.